In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

Ex Input:
SECTION 1. DEVELOPMENT OF BEST PRACTICES FOR THE USE OF PRESCRIPTION 
              OPIOIDS.

    (a) Definitions.--In this section--
            (1) the term ``Secretary'' means the Secretary of Health 
        and Human Services; and
            (2) the term ``task force'' means the Pain Management Best 
        Practices Inter-Agency Task Force convened under subsection 
        (b).
    (b) Inter-Agency Task Force.--Not later than December 14, 2018, the 
Secretary, in cooperation with the Secretary of Veterans Affairs, the 
Secretary of Defense, and the Administrator of the Drug Enforcement 
Administration, shall convene a Pain Management Best Practices Inter-
Agency Task Force to review, modify, and update, as appropriate, best 
practices for pain management (including chronic and acute pain) and 
prescribing pain medication.
    (c) Membership.--The task force shall be comprised of--
            (1) representatives of--
                    (A) the Department of Health and Human Services;
                    (B) the Department of Veterans Affairs;
                    (C) the Food and Drug Administration;
                    (D) the Department of Defense;
                    (E) the Drug Enforcement Administration;
                    (F) the Centers for Disease Control and Prevention;
                    (G) the Health Resources and Services 
                Administration;
                    (H) the Indian Health Service;
                    (I) the National Academy of Medicine;
                    (J) the National Institutes of Health;
                    (K) the Office of National Drug Control Policy;
                    (L) the Substance Abuse and Mental Health Services 
                Administration; and
                    (M) the Office of Women's Health;
            (2) State medical boards;
            (3) subject to subsection (e), physicians, dentists, and 
        nonphysician prescribers;
            (4) hospitals;
            (5) subject to subsection (e), pharmacists and pharmacies;
            (6) first responders;
            (7) experts in the fields of pain research and addiction 
        research;
            (8) experts in the fields of adolescent and young adult 
        addiction research;
            (9) representatives of--
                    (A) pain management professional organizations;
                    (B) the mental health treatment community;
                    (C) the addiction treatment and recovery community;
                    (D) pain advocacy groups;
                    (E) veteran service organizations; and
                    (F) groups with expertise on overdose reversal;
            (10) a person in recovery from addiction to medication for 
        chronic pain;
            (11) a person in recovery from addiction to medication for 
        chronic pain, whose addiction began in adolescence or young 
        adulthood;
            (12) a person with chronic pain;
            (13) an expert on active duty military, armed forces 
        personnel, and veteran health and prescription opioid 
        addiction;
            (14) an expert in the field of minority health; and
            (15) other stakeholders, as the Secretary determines 
        appropriate.
    (d) Condition on Participation on Task Force.--An individual 
representing a profession or entity described in paragraph (3) or (5) 
of subsection (c) may not serve as a member of the task force unless 
such individual--
            (1) is currently licensed in a State in which such 
        individual is practicing (as defined by such State) such 
        profession (or, in the case of an individual representing an 
        entity, a State in which the entity is engaged in business); 
        and
            (2) is currently practicing (as defined by such State) such 
        profession (or, in the case of an individual representing an 
        entity, the entity is in operation).
    (e) Duties.--The task force shall--
            (1) not later than 180 days after the date on which the 
        task force is convened under subsection (b), review, modify, 
        and update, as appropriate, best practices for pain management 
        (including chronic and acute pain) and prescribing pain 
        medication, taking into consideration--
                    (A) existing pain management research;
                    (B) research on trends in areas and communities in 
                which the prescription opioid abuse rate and fatality 
                rate exceed the national average prescription opioid 
                abuse rate and fatality rate;
                    (C) recommendations from relevant conferences and 
                existing relevant evidence-based guidelines;
                    (D) ongoing efforts at the State and local levels 
                and by medical professional organizations to develop 
                improved pain management strategies, including 
                consideration of differences within and between classes 
                of opioids, the availability of opioids with abuse 
                deterrent technology, and pharmacological, 
                nonpharmacological, medical device alternatives to 
                opioids to reduce opioid monotherapy in appropriate 
                cases and the coordination of information collected 
                from State prescription drug monitoring programs for 
                the purpose of preventing the diversion of pain 
                medication;
                    (E) ongoing efforts at the Federal, State, and 
                local levels to examine the potential benefits of 
                electronic prescribing of opioids, including any public 
                comments collected in the course of those efforts;
                    (F) the management of high-risk populations, other 
                than populations who suffer pain, who--
                            (i) may use or be prescribed 
                        benzodiazepines, alcohol, and diverted opioids; 
                        or
                            (ii) receive opioids in the course of 
                        medical care;
                    (G) the distinct needs of adolescents and young 
                adults with respect to pain management, pain 
                medication, substance use disorder, and medication-
                assisted treatment;
                    (H) the 2016 Guideline for Prescribing Opioids for 
                Chronic Pain issued by the Centers for Disease Control 
                and Prevention;
                    (I) the practice of co-prescribing naloxone for 
                both pain patients receiving chronic opioid therapy and 
                patients being treated for opioid use disorders;
                    (J) research that has been, or is being, conducted 
                or supported by the Federal Government on prevention 
                of, treatment for, and recovery from substance use by 
                and substance use disorders among adolescents and young 
                adults relative to any unique circumstances (including 
                social and biological circumstances) of adolescents and 
                young adults that may make adolescent-specific and 
                young adult-specific treatment protocols necessary, 
                including any effects that substance use and substance 
                use disorders may have on brain development and the 
                implications for treatment and recovery;
                    (K) Federal non-research programs and activities 
                that address prevention of, treatment for, and recovery 
                from substance use by and substance use disorders among 
                adolescents and young adults, including an assessment 
                of the effectiveness of such programs and activities 
                in--
                            (i) preventing substance use by and 
                        substance use disorders among adolescents and 
                        young adults;
                            (ii) treating such adolescents and young 
                        adults in a way that accounts for any unique 
                        circumstances faced by adolescents and young 
                        adults; and
                            (iii) supporting long-term recovery among 
                        adolescents and young adults; and
                    (L) gaps that have been identified by Federal 
                officials and experts in Federal efforts relating to 
                prevention of, treatment for, and recovery from 
                substance use by and substance use disorders among 
                adolescents and young adults, including gaps in 
                research, data collection, and measures to evaluate the 
                effectiveness of Federal efforts, and the reasons for 
                such gaps;
            (2) solicit and take into consideration public comment on 
        the practices developed under paragraph (1), amending such best 
        practices if appropriate;
            (3) develop a strategy for disseminating information about 
        the best practices developed under paragraphs (1) and (2) to 
        prescribers, pharmacists, State medical boards, educational 
        institutions that educate prescribers and pharmacists, and 
        other parties, as the Secretary determines appropriate;
            (4) review, modify, and update best practices for pain 
        management and prescribing pain medication, specifically as it 
        pertains to physician education and consumer education; and
            (5) examine and identify--
                    (A) the extent of the need for the development of 
                new pharmacological, nonpharmacological, and medical 
                device alternatives to opioids;
                    (B) the current status of research efforts to 
                develop such alternatives; and
                    (C) the pharmacological, nonpharmacological, and 
                medical device alternatives to opioids that are 
                currently available that could be better utilized.
    (f) Consideration of Study Results.--In reviewing, modifying, and 
updating, best practices for pain management and prescribing pain 
medication, the task force shall take into consideration existing 
private sector, State, and local government efforts related to pain 
management and prescribing pain medication.
    (g) Limitation.--The task force shall not have rulemaking 
authority.
    (h) Report.--Not later than 270 days after the date on which the 
task force is convened under subsection (b), the task force shall 
submit to Congress a report that includes--
            (1) the strategy for disseminating best practices for pain 
        management (including chronic and acute pain) and prescribing 
        pain medication, as developed under subsection (e);
            (2) the results of a feasibility study on linking the best 
        practices described in paragraph (1) to receiving and renewing 
        registrations under section 303(f) of the Controlled Substances 
        Act (21 U.S.C. 823(f));
            (3) recommendations for effectively applying the best 
        practices described in paragraph (1) to improve prescribing 
        practices at medical facilities, including medical facilities 
        of the Veterans Health Administration and Indian Health 
        Service;
            (4) the modified and updated best practices described in 
        subsection (e)(4); and
            (5) the results of the examination and identification 
        conducted pursuant to subsection (e)(4), and recommendations 
        regarding--
                    (A) the development of new pharmacological, 
                nonpharmacological, and medical device alternatives to 
                opioids; and
                    (B) the improved utilization of pharmacological, 
                nonpharmacological, and medical device alternatives to 
                opioids that are currently available.

            Passed the House of Representatives May 11, 2016.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.

Ex Output:
(Sec. 1) This bill requires the Department of Health and Human Services to convene a Pain Management Best Practices Inter-Agency Task Force to: (1) review, modify, and update best practices for pain management and prescribing pain medication; and (2) examine and identify the need for, development of, and availability of medical alternatives to opioids (drugs with effects similar to opium, such as certain pain medications). The task force must submit a report that includes: (1) the modified and updated best practices; (2) a strategy for disseminating the best practices; (3) the feasibility of linking the best practices to Drug Enforcement Administration registration of manufacturers, distributors, and dispensers of controlled substances; (4) recommendations for effectively applying the best practices at medical facilities; and (5) recommendations regarding medical alternatives to opioids.


Ex Input:
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Student Loan Fairness Consolidation 
Act of 2003''.

SEC. 2. AUTHORITY TO REFINANCE EXISTING CONSOLIDATION LOANS.

    (a) FFEL Consolidation Loans.--Section 428C(a)(3)(B) of the Higher 
Education Act of 1965 (20 U.S.C. 1078-3(a)(3)(B)) is amended by adding 
at the end the following new clause:
            ``(ii) Notwithstanding clause (i) of this subparagraph, a 
        borrower of a consolidation loan on which the interest is 
        established at a fixed rate under section 427A, 428C(c), or 455 
        may obtain a subsequent consolidation loan for the purposes of 
        refinancing such earlier consolidation loan at a variable rate 
        of interest under section 427A(m) or 455(b)(8), except that the 
        authority to refinance a consolidation loan under this clause 
        shall not apply to a consolidation loan that was used 
        exclusively to repay loans made under section 428B or Federal 
        Direct PLUS Loans (or both such loans).''.
    (b) Parallel Terms for Federal Direct Consolidation Loans.--Section 
455(a) of the Higher Education Act of 1965 (20 U.S.C. 1087e(a)) is 
amended--
            (1) in paragraph (1), by inserting ``428C,'' after 
        ``428B,''; and
            (2) in paragraph (2)--
                    (A) by striking ``and'' at the end of subparagraph 
                (B);
                    (B) by redesignating subparagraph (C) as 
                subparagraph (D); and
                    (C) by inserting after subparagraph (B) the 
                following:
                    ``(C) section 428C shall be known as `Federal 
                Direct Consolidation Loans'.''.

SEC. 3. AVAILABILITY OF VARIABLE INTEREST RATE CONSOLIDATION LOANS.

    (a) FFEL Consolidation Loans.--Section 427A of the Higher Education 
Act of 1965 (20 U.S.C. 1077a) is amended--
            (1) by redesignating subsection (m) and (n) as subsections 
        (n) and (o), respectively; and
            (2) by inserting after subsection (l) the following:
    ``(m) Variable Interest Rate Consolidation Loans.--
            ``(1) Variable rate.--Notwithstanding subsections (h), (k), 
        and (l), with respect to any loan made pursuant to section 428C 
        for which the first disbursement is made on or after the date 
        of enactment of the Student Loan Fairness Consolidation Act of 
        2003, the applicable rate of interest shall, during any 12-
        month period beginning on July 1 and ending on June 30, be 
        determined on the preceding June 1 and be equal to--
                    ``(A) the bond equivalent rate of 91-day Treasury 
                bills auctioned at the final auction held prior to such 
                June 1; plus
                    ``(B) 2.3 percent,
        except that such rate shall not exceed 8.25 percent.
            ``(2) Recovery of excess interest.--If, with respect to a 
        consolidation loan on which the applicable interest rate is 
        determined under this subsection, the applicable interest rate 
        for any 3-month period exceeds the special allowance rate 
        applicable to such loan under section 438(b)(2)(I) for such 
        period, then an adjustment shall be made--
                    ``(A) by calculating the excess interest in the 
                amount computed under paragraph (3) of this subsection; 
                and
                    ``(B) by crediting the excess interest to the 
                Government.
            ``(3) Amount of adjustment.--The amount of any adjustment 
        of interest on a loan to be made under this subsection for any 
        quarter shall be equal to--
                    ``(A) the applicable interest rate minus the 
                special allowance rate determined under section 
                438(a)(2)(I); multiplied by
                    ``(B) the average daily principal balance of the 
                loan (not including unearned interest added to 
                principal) during such calendar quarter; divided by
                    ``(C) four.
            ``(4) Inapplicability to consolidation loans used to repay 
        plus loans.--The provisions of paragraph (1) of this subsection 
        shall not apply to a consolidation loan that was used 
        exclusively to repay loans made under section 428B or Federal 
        Direct PLUS Loans (or both such loans).''.
    (b) Federal Direct Consolidation Loans.--Section 455(b) of the 
Higher Education Act of 1965 (20 U.S.C. 1087e(b)) is amended--
            (1) by redesignating paragraphs (8) and (9) as paragraphs 
        (9) and (10), respectively; and
            (2) by inserting after paragraph (7) the following:
            ``(8) Variable interest rate consolidation loans.--
                    ``(A) Variable rate.--Notwithstanding the preceding 
                paragraphs of this subsection, with respect to any 
                Federal Direct Consolidation Loan for which the first 
                disbursement is made on or after the date of enactment 
                of the Student Loan Fairness Consolidation Act of 2003, 
                the applicable rate of interest shall, during any 12-
                month period beginning on July 1 and ending on June 30, 
                be determined on the preceding June 1 and be equal to--
                            ``(i) the bond equivalent rate of 91-day 
                        Treasury bills auctioned at the final auction 
                        held prior to such June 1; plus
                            ``(ii) 2.3 percent,
                except that such rate shall not exceed 8.25 percent.
                    ``(B) Inapplicability to consolidation loans used 
                to repay plus loans.--The provisions of this subsection 
                shall not apply to a consolidation loan that was used 
                exclusively to repay loans made under section 428B or 
                Federal Direct PLUS Loans (or both such loans).''.
    (c) Conforming Amendment.--Section 438(b)(2)(I) is amended by 
striking ``section 427A(k)(4) or (l)(3)'' each place it appears in 
clauses (iv) and (vi) and inserting ``section 427A(k)(4), (l)(3), or 
(m)''.

Ex Output:
Student Loan Fairness Consolidation Act of 2003 - Amends the Higher Education Act of 1965 to revise student aid requirements for Federal consolidation loans under the Federal Family Education Loan program, and establish parallel requirements under a Federal Direct Consolidation Loan program, to: (1) allow borrowers to refinance existing consolidation loans; and (2) make available variable interest rate consolidation loans. Excludes consolidation loans for repaying Federal PLUS loans (taken out by parents of students) from such provisions for refinancing and variable interest rates.


Ex Input:
SECTION 1. SHORT TITLE.

    (a) Short Title.--This Act may be cited as the ``Cancer Care 
Planning and Communications Act of 2018''.
    (b) Findings.--Congress makes the following findings:
            (1) Cancer care in the United States is often described as 
        the best in the world because patients have access to many 
        treatment options, including cutting-edge therapies that save 
        lives and improve the quality of life.
            (2) Access to the best treatment options is not equal 
        across all populations and in all communities. The 1999 
        Institute of Medicine report entitled ``The Unequal Burden of 
        Cancer'' found that low-income people often lack access to 
        adequate cancer care and that ethnic minorities have not 
        benefitted fully from cancer treatment advances.
            (3) In addition, despite access to high-quality treatment 
        options for many, individuals with cancer often do not have 
        access to a cancer care system that incorporates shared 
        decision-making and the coordination of all elements of care.
            (4) Cancer survivors often experience the under-diagnosis 
        and under-treatment of the symptoms of cancer and side effects 
        of cancer treatment, a problem that begins at the time of 
        diagnosis and may become more severe with disease progression 
        and at the end of life. The failure to treat the symptoms, side 
        effects, and late effects of cancer and cancer treatment may 
        have a serious adverse impact on the health, survival, well-
        being, and quality of life of cancer survivors.
            (5) Individuals with cancer often do not participate in a 
        shared decision-making process that considers all treatment 
        options and do not benefit from coordination of all elements of 
        active treatment and palliative care.
            (6) Quality cancer care should incorporate access to 
        psychosocial services and management of the symptoms of cancer 
        and the symptoms of cancer treatment, including pain, nausea, 
        vomiting, fatigue, and depression.
            (7) Quality cancer care should include a means for engaging 
        cancer survivors in a shared decision-making process that 
        produces a comprehensive care summary and a plan for follow-up 
        care after primary treatment to ensure that cancer survivors 
        have access to follow-up monitoring and treatment of possible 
        late effects of cancer and cancer treatment, including 
        appropriate psychosocial services.
            (8) The Institute of Medicine report entitled ``Ensuring 
        Quality Cancer Care'' described the elements of quality care 
        for an individual with cancer to include--
                    (A) the development of initial treatment 
                recommendations by an experienced health care provider;
                    (B) the development of a plan for the course of 
                treatment of the individual and communication of the 
                plan to the individual;
                    (C) access to the resources necessary to implement 
                the course of treatment;
                    (D) access to high-quality clinical trials;
                    (E) a mechanism to coordinate services for the 
                treatment of the individual; and
                    (F) psychosocial support services and compassionate 
                care for the individual.
            (9) In its report ``From Cancer Patient to Cancer Survivor: 
        Lost in Transition'', the Institute of Medicine recommended 
        that individuals with cancer completing primary treatment be 
        provided a comprehensive summary of their care along with a 
        follow-up survivorship plan of treatment.
            (10) In ``Cancer Care for the Whole Patient'', the 
        Institute of Medicine stated that the development of a plan 
        that includes biomedical and psychosocial care should be a 
        standard for quality cancer care in any quality measurement 
        system.
            (11) The Commission on Cancer has encouraged survivorship 
        care planning by making the development of such plans for 
        patients one of the standards of accreditation for cancer care 
        providers, but cancer care professionals report difficulties 
        completing the plans.
            (12) Because more than half of all cancer diagnoses occur 
        among elderly Medicare beneficiaries, addressing cancer care 
        inadequacies through Medicare reforms will provide benefits to 
        millions of Americans. Providing Medicare beneficiaries more 
        routine access to cancer care plans and survivorship care plans 
        is a key to shared decisionmaking and better coordination of 
        care.
            (13) Important payment and delivery reforms that 
        incorporate cancer care planning and coordination are already 
        being tested in the Medicare program; the Oncology Care Model 
        has been implemented in a number of oncology practices, and 
        additional models that will include care planning have been 
        proposed.
            (14) The alternative payment models, including the Oncology 
        Care Model, provide access to cancer care planning for Medicare 
        beneficiaries who receive their cancer care in practices that 
        are part of the Oncology Care Model. Other Medicare 
        beneficiaries who are not enrolled in these delivery 
        demonstrations may not have access to a cancer care plan or 
        appropriate care coordination.
            (15) The failure to provide a cancer care plan to patients 
        in many care settings relates in part to inadequate Medicare 
        payment for such planning and coordination services.
            (16) Changes in Medicare payment for cancer care planning 
        and coordination will support shared decisionmaking that 
        reviews all treatment options and will contribute to improved 
        care for individuals with cancer from the time of diagnosis 
        through the end of the life. Medicare payment for cancer care 
        planning may begin a reform process that helps us realize the 
        well-planned and well-coordinated cancer care that has been 
        recommended by the Institute of Medicine/National Academy of 
        Medicine and that is preferred by cancer patients across the 
        Nation.

SEC. 2. COVERAGE OF CANCER CARE PLANNING AND COORDINATION SERVICES.

    (a) In General.--Section 1861 of the Social Security Act (42 U.S.C. 
1395x) is amended--
            (1) in subsection (s)(2)--
                    (A) by striking ``and'' at the end of subparagraph 
                (FF);
                    (B) by adding ``and'' at the end of subparagraph 
                (GG); and
                    (C) by adding at the end the following new 
                subparagraph:
            ``(HH) cancer care planning and coordination services (as 
        defined in subsection (jjj))''; and
            (2) by adding at the end the following new subsection:

            ``Cancer Care Planning and Coordination Services

    ``(jjj)(1) The term `cancer care planning and coordination 
services' means--
            ``(A) with respect to an individual who is diagnosed with 
        cancer, the development of a treatment plan by a physician, 
        nurse practitioner, or physician assistant that--
                    ``(i) includes an assessment of the individual's 
                diagnosis, health status, treatment needs, functional 
                status, pain control, and psychosocial needs;
                    ``(ii) engages the individual in a shared decision-
                making process that reviews all treatment options;
                    ``(iii) details, to the greatest extent practicable 
                all aspects of the care to be provided to the 
                individual with respect to the treatment of such 
                cancer, including any curative treatment, comprehensive 
                symptom management, and palliative care;
                    ``(iv) is furnished in person, in written form, to 
                the individual within a period specified by the 
                Secretary that is as soon as practicable after the date 
                on which the individual is so diagnosed;
                    ``(v) is furnished, to the greatest extent 
                practicable, in a form that appropriately takes into 
                account cultural and linguistic needs of the individual 
                in order to make the plan accessible to the individual; 
                and
                    ``(vi) is in accordance with standards determined 
                by the Secretary to be appropriate;
            ``(B) with respect to an individual for whom a treatment 
        plan has been developed under subparagraph (A), the revision of 
        such treatment plan as necessary to account for any substantial 
        change in the condition of the individual, recurrence of 
        disease, changes in the individual's treatment preferences, or 
        significant revision of the elements of curative care or 
        symptom management for the individual, if such revision--
                    ``(i) is in accordance with clauses (i), (ii), (iv) 
                and (v) of such subparagraph; and
                    ``(ii) is furnished in written form to the 
                individual within a period specified by the Secretary 
                that is as soon as practicable after the date of such 
                revision;
            ``(C) with respect to an individual who has completed the 
        primary treatment for cancer, as defined by the Secretary, the 
        development of a follow-up survivorship care plan that--
                    ``(i) includes an assessment of the individual's 
                diagnosis, health status, treatment needs, functional 
                status, pain control, and psychosocial needs;
                    ``(ii) engages the individual in a shared decision-
                making process that reviews all survivorship care 
                options;
                    ``(iii) describes the elements of the primary 
                treatment, including symptom management and palliative 
                care, furnished to such individual;
                    ``(iv) provides recommendations for the subsequent 
                care of the individual with respect to the cancer 
                involved;
                    ``(v) is furnished, in person, in written form, to 
                the individual within a period specified by the 
                Secretary that is as soon as practicable after the 
                completion of such primary treatment;
                    ``(vi) is furnished, to the greatest extent 
                practicable, in a form that appropriately takes into 
                account cultural and linguistic needs of the individual 
                in order to make the plan accessible to the individual; 
                and
                    ``(vii) is in accordance with standards determined 
                by the Secretary to be appropriate; and
            ``(D) with respect to an individual for whom a follow-up 
        cancer care plan has been developed under subparagraph (C), the 
        revision of such plan as necessary to account for any 
        substantial change in the condition of the individual, 
        diagnosis of a second cancer, change in the individual's 
        preference for survivorship care, or significant revision of 
        the plan for follow-up care, if such revision--
                    ``(i) is in accordance with clauses (i), (ii), 
                (iii), (v), and (vi) of such subparagraph; and
                    ``(ii) is furnished in written form to the 
                individual within a period specified by the Secretary 
                that is as soon as practicable after the date of such 
                revision.
    ``(2) The Secretary shall establish standards to carry out 
paragraph (1) in consultation with appropriate organizations 
representing suppliers and providers of services related to cancer 
treatment and organizations representing survivors of cancer. Such 
standards shall include standards for determining the need and 
frequency for revisions of the treatment plans and follow-up 
survivorship care plans based on changes in the condition of the 
individual or elements and intent of treatment and standards for the 
communication of the plan to the individual.
    ``(3) In this subsection, the term `shared decision-making process' 
means, with respect to an individual, a process in which the individual 
and the individual's health care providers consider the individual's 
diagnosis, treatment options, the medical evidence related to treatment 
options, the risks and benefits of all treatment options, and the 
individual's preferences regarding treatment, and then jointly develop 
and implement a treatment plan.''.
    (b) Payment Under Physician Fee Schedule.--
            (1) In general.--Section 1848(j)(3) of the Social Security 
        Act (42 U.S.C. 1395w-4(j)(3)) is amended by inserting ``(HH),'' 
        after ``health risk assessment),''.
            (2) Initial rates.--Unless the Secretary of Health and 
        Human Services otherwise provides, the payment rate specified 
        under the physician fee schedule under the amendment made by 
        paragraph (1) for cancer care planning and coordination 
        services shall be the same payment rate as provided for 
        transitional care management services (as defined in CPT code 
        99496).
    (c) Effective Date.--The amendments made by this section shall 
apply to services furnished on or after the first day of the first 
calendar year that begins after the date of the enactment of this Act.

Ex Output:

Cancer Care Planning and Communications Act of 2018 This bill&nbsp;provides for&nbsp;Medicare&nbsp;coverage and payment&nbsp;of cancer care planning and coordination services.